ClinicalTrials.gg
RecruitingNCT06517017UltraFrailMMUpdated Oct 23, 2026

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

A Phase 2 interventional study of Isatuximab in Multiple Myeloma and Plasma Cell Leukemia, sponsored by University of Utah. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Primary conditionLeukemia, Plasma CellRegistry: Multiple MyelomaReclassifiedWhy we changed it
Registry
Multiple Myeloma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Plasma Cell
Why
  1. The study's listed conditions name Leukemia, Plasma Cell, a narrower term within Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Utah · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 23, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Leukemia, Plasma Cell with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Leukemia, Plasma Cell · United States.

Planned enrollment
15th of 29
40 · median 40
Started
2025
the only one that year
Phase 2
14 of 31
5 open now
Registered
30th of 31
by date
Lead sponsor
2 of 31
University of Utah

Among the 31 studies in Leukemia, Plasma Cell with a site in United States, this one is the 15th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2025, is one of 14 in phase 2, and was the 30th registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

8 of the 31 studies in Leukemia, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Leukemia, Plasma Cell with a site in United States, or all of them as a file.
02

Study summary

Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality. The investigators hypothesize that a go-slow gentle approach to starting treatment in such patients, starting with just Isatuximab and dexamethasone with a gentle introduction to lenalidomide third cycle onwards, may improve treatment adherence and quality of life. The goal of this clinical trial is to learn if a go-slow approach to treating MM in ultra-frail patients may improve the ability to adhere to treatment and improve quality of life.

03

Conditions studied

  • Multiple Myeloma
  • Plasma Cell Leukemia

Browse trials for

04

In context

Leukemia, Plasma Cell Reclassified

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

This study's planned enrollment of 40 is above the median of 27 across 53 interventional studies indexed under Leukemia, Plasma Cell.

Browse Leukemia, Plasma Cell studies →

Lead sponsor

University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.

Compared within Leukemia, Plasma Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Myeloma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject aged ≥ 18 years.
  • confirmed myeloma and/or Plasma Cell Leukemia who are newly diagnosed and having completed ≤ 1 prior cycle of myeloma treatment.
  • For female subjects of : Negative pregnancy test or evidence of status or evidence of permanent surgical sterilization (bilateral oophorectomy or hysterectomy). The post-menopausal status will be defined as having been amenorrheic for 24 months without an alternative medical cause.
  • Subjects must be willing to follow requirements listed in the protocol, agree to participate in the Lenalidomide REMS program, and have signed the Patient-Physician Agreement Form.
  • Male subjects must agree to use a latex condom during intercourse for the duration of study therapy as described in the protocol, even if he has undergone a successful vasectomy.
  • Recovery to baseline or ≤ Grade 1 v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy per the treating investigator.
  • Able to provide and willing to sign an approved consent form that conforms to federal and institutional guidelines.
  • IMWG defined frailty score ≥ 3. IMWG definition available here: http://www.myelomafrailtyscorecalculator.net

Exclusion criteria

Exclusion Criteria:

  • Receiving other agents.
  • Any condition that would, in the Investigator's judgment, compromise the subject's ability to understand the subject information, give , and/or contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, [subjects may not receive the drug through a feeding tube], social/ psychological issues, etc.)
  • Known prior severe ( v5.0 Grade ≥ 3) to investigational product (IP) or any component in its formulations. This includes hypersensitivity or history of intolerance to , mannitol, pregelatinized starch, sodium stearyl fumarate, histidine (as base and hydrochloride salt), arginine hydrochloride, poloxamer 188, sucrose or any of the other components of study intervention that are not amenable to premedication with steroids and H2 blockers or would prohibit further treatment with these agents.
  • Subjects currently taking prohibited medications as described in the protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Combination Treatment

    Isatuximab

    Drug: Isatuximab

Interventions

  • Subcutaneous isatuximab will be administered weekly on a 28-day cycle during the first two cycles, and every two weeks of a 28-day cycle thereafter. Dexamethasone will be administered on the days of isatuximab administration and can be discontinued after two cycles of therapy, or continued at discretion of investigator. Lenalidomide, will be added after two cycles of therapy have been completed.

    Also known as: Dexamethasone, Lenalidomide

07

What researchers measure

Primary outcomes

  1. Completion rate of 9 cycles of treatment

    Assess the feasibility of approach incorporating the use of isatuximab and dexamethasone with the subsequent addition of lenalidomide from the third cycle onwards in ultra-frail patients with myeloma

    Time frame: At the end of 9 cycles of treatment (each cycle is 28 days)

Secondary outcomes

  1. Change in quality of life as per the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 domain

    Assess if an approach incorporating the use of isatuximab and dexamethasone with the subsequent addition of a lenalidomide in ultra-frail patients with myeloma leads to an improvement in quality of life as measured by the EORTC score. The questionnaire has 10 subscales, each with a score range of 0 to 100 points. Higher scores on the functional scales and global quality of life indicate better functioning, while higher scores on the symptom scales indicate a higher symptom burden. The QLQ-C30 summary score is calculated by averaging the scores of the 13 scales and items, with a higher score indicating a better health-related quality of life (HRQoL).

    Time frame: At the end of 4 cycles of treatment (each cycle is 28 days)

  2. Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type

    Assess the safety and tolerability of isatuximab, lenalidomide and dexamethasone in the study population.

    Time frame: At study completion. Participants will be enrolled in study for about 3 years.

  3. Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 5.0)

    Assess the safety and tolerability of isatuximab, lenalidomide and dexamethasone in the study population.

    Time frame: At study completion. Participants will be enrolled in study for about 3 years.

  4. Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness

    Assess the safety and tolerability of isatuximab, lenalidomide and dexamethasone in the study population.

    Time frame: At study completion. Participants will be enrolled in study for about 3 years.

  5. Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration

    Assess the safety and tolerability of isatuximab, lenalidomide and dexamethasone in the study population.

    Time frame: At study completion. Participants will be enrolled in study for about 3 years.

  6. Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by relationship to study treatment

    Assess the safety and tolerability of isatuximab, lenalidomide and dexamethasone in the study population.

    Time frame: At study completion. Participants will be enrolled in study for about 3 years.

  7. Overall survival (OS)

    Assess overall survival in this study population

    Time frame: Time from registration until 3 years from start of therapy or death from any cause.

08

Study locations

1 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2024
First posted
Jul 24, 2024
StartActual
Oct 9, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • University of Illinois Cancer Center · Chicago, United States
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added
    Show site
    • University of Illinois Cancer Center · Chicago, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06517017
Lead sponsor
University of Utah
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jul 24, 2024
Start date
Oct 9, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Rachel Kingsford
Contact
rachel.kingsford@hci.utah.edu
801-585-0115
Ghulam Rehman Mohyuddin, MBBS
principal investigator · Huntsman Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion